Want to join the conversation?
For 2Q16, $MYL posted adjusted GM of 56%, up approx. 200 BP vs. 2Q15 and 1Q16 due to new product introductions and favorable Specialty sales. Adjusted R&D expense rose slightly vs. 2Q15 as the company continues to invest in its respiratory, insulin and biologics programs. SG&A remained unchanged at approx. 21% of total revenues.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?